Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Velinotamig
Therapeutic Area : Immunology
Study Phase : IND Enabling
Sponsor : Cullinan Therapeutics
Deal Size : $712.0 million
Deal Type : Licensing Agreement
Cullinan's $700M Pact for BCMA Bispecific to Pair with Other TCE
Details : Under the licensing agreement, Cullinan will holds the exclusive rights to develop and commercialize GR-1803 (velinotamig) in all disease areas globally outside of Greater China.
Product Name : GR-1803
Product Type : Antibody
Upfront Cash : $20.0 million
June 05, 2025
Lead Product(s) : Velinotamig
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Sponsor : Cullinan Therapeutics
Deal Size : $712.0 million
Deal Type : Licensing Agreement
Reset All
